Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
about
Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes.Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentNeuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study.Successful use of bevacizumb and paclitaxel in a male breast cancer with liver metastases.Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer.Weighed, measured, and still searching: bevacizumab in the treatment of unselected patients with advanced breast cancerPublication of tumor marker research results: the necessity for complete and transparent reporting.A rectovaginal fistula after treatment with bevacizumab. A dangerous side effect needing emergency treatmentStrategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug.A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers.Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance.VEGF-induced intracellular Ca2+ oscillations are down-regulated and do not stimulate angiogenesis in breast cancer-derived endothelial colony forming cells.Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment.The quaternary state of polymerized human hemoglobin regulates oxygenation of breast cancer solid tumors: A theoretical and experimental study.VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.mouse study identifies tumour growth kinetics as biomarkers for the outcome of anti-angiogenic treatment
P2860
Q27348042-ABF9B79B-1902-4BAB-80FA-28E3E8C4D92DQ28073057-555CAFDB-719D-4B91-B605-FEDCE9B0402FQ33789563-FC068192-8496-4E65-95F6-968F39783020Q34415276-41E2CABF-A1CF-4F24-84AC-4756738B5B89Q34609696-66EED82D-1548-4AAE-B619-4DED7EDBE30DQ35642338-90FF8EEA-3C4E-4695-A195-E1E917F38EB1Q36417739-FCF28000-DAAD-4C41-838E-5A900DC7F7FDQ36797605-92D61E90-A1C0-4C22-926F-CEFFF6455E17Q38046514-DD12B3A4-CC04-4D36-9EC2-12E0AAB8DBF9Q38130312-BB255BA7-D555-46E6-AED3-C95C422CC5AAQ38259982-54867D7E-0994-43BE-A493-57198FF2530AQ38723771-A681EA68-D153-4134-A3E1-96FE93F7F910Q38839151-E789C8CE-878E-4B4E-B68D-33C83EBD6786Q41186469-4CC93339-ADAD-49FA-BCDD-44264F857C24Q41961052-27DFD369-D65D-4233-8D5F-789F1CA6AE41Q42481201-E8396BA5-DCD9-46C7-9E23-89AB85C50F79Q47098476-D818B3DB-656A-43B1-A3A9-3EA5AE41F1E0Q47137711-166EE85E-4578-4939-AA19-3304F79342AEQ47228068-D51F503B-508E-4F35-8EA6-3BB8A7B77865Q50133464-FC6ECA79-B482-47E9-A084-EA53F70BE782Q53025494-7DDBF8EA-262C-4991-8D77-254BBA523EECQ58718463-023FEC37-15C1-4BF1-8CD1-EBD9168E98F9
P2860
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
@ast
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
@en
type
label
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
@ast
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
@en
prefLabel
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
@ast
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
@en
P2093
P2860
P1476
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
@en
P2093
Alberto J Montero
Charles Vogel
Gilberto Lopes
Mauricio Escobar
Stefan Glück
P2860
P2888
P356
10.1007/S11912-011-0202-Z
P577
2012-02-01T00:00:00Z